Causes & What We KnowA New Tool for Understanding Type 1 Diabetes: Safer Lab Models of Beta Cell DamageResearch, trials, devices, and safety notices — labeled by evidence strength so you can tell solid science from hype.
1598 evidence-labeled articles across 6 topics
A clinical trial is testing tegoprubart, a targeted immunotherapy, alongside islet cell transplants in people with type…
Read →
Recent research shows that automated insulin delivery systems help people with Type 1 diabetes spend more time in their…
Read →
A new study from Japan suggests that adults with Type 1 diabetes who follow low-carbohydrate eating patterns—especially…
Read →
A large Swedish study examined whether maternal autoimmune conditions during pregnancy influence whether children develo…
Read →Researchers have developed a more precise way to study how pancreatic beta cells are damaged in Type 1 diabetes, using l…
Read →
A new study from India reveals the hidden struggles mothers face when schools lack preparation for managing their child'…
Read →Pulled from official registries and public research sources, then labeled by evidence strength before publication.
Saved on this device only. Matching items rise on Today. No health profile required.
34 items from 4 live sources. Feed checked Nov 3, 2026, 9:17 AM GMT-5.
Tandem Diabetes Care, Inc. ( Tandem ) has identified that certain Tandem Mobi insulin pumps may generate false-positive occlusion alarms when no actual insulin flow obstruction is present. Investigation determined that increased friction within the drive module can reduce available motor power and, under certain conditions, cause motor speed to fall below the occlusion detecti... Action: On 9/23/2026, "URGENT MEDICAL DEVICE CORRECTION" recall and correction notices were emailed to customers who were asked to do th...
A software defect in which existing users who had previously configured and enabled the long-acting dose reminder feature in version 1.2.0 or earlier experienced failure of the long-acting dose reminder after updating their app to version 1.2.1. The long-acting dose reminder is an optional feature that, when enabled, triggers a notification at the scheduled time to remind user... Action: On 09/14/2026, customers were contacted via SMS, emailed or via an "URGENT MEDICAL DEVICE CORRECTION" Letter informing them that...
RECRUITING, PHASE1, PHASE2. Interventions: Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab. Locations: Los Angeles, California, United States | San Francisco, California, United States | New Haven, Connecticut, United States. This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons a...
RECRUITING, PHASE2. Interventions: High Dose SAB-142, Low Dose SAB-142, Placebo. Locations: San Francisco, California, United States | San Jose, California, United States | Aurora, Colorado, United States. This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
RECRUITING, NA. Interventions: Insulin Self-Management Know-Find-Solve Activity Book, Routine education. Locations: Istanbul, Turkey (Türkiye). Children with type 1 diabetes require lifelong insulin therapy. However, improper management of insulin therapy may lead to serious, potentially life-threatening complications. The aim of this study is to examine the effect of an activity book developed for insulin therapy on insulin self-management among children...
RECRUITING, PHASE3. Interventions: Baricitinib, Placebo. Locations: Santa Barbara, California, United States | Tallahassee, Florida, United States | Iowa City, Iowa, United States. The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Some MiniMed Flex insulin pumps were released with missing (i.e., devices with no result or abort test results are presumed to have failed) or failed verification test results in one or more of 9 functional tests. The unverified/failed pumps released to users potentially have one or more of the following issues: inoperable pump at setup, lack of protection for moisture exposur... Action: On 08/20/2026, Technical Support called affected customers to inform that, MiniMed identified an issue in which certain MiniMed...
A beta (early-release) version of the iOS application, version 2.13 (TestFlight) had a software issue preventing successful pairing of the t:slim application with Abbott FreeStyle Libre 3 Plus (FSL3P) continuous glucose monitoring (CGM) sensors, resulting in the insulin pump being unable to establish a near-field communication (NFC) connection with the CGM and requiring FSL3P... Action: On 07/16/2026, an "URGENT MEDICAL DEVICE CORRECTION" communication was sent via certified mail to customers informing them that a...
Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...
Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...
Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...
For MiniMed Go app version 1.0.0 and 1.1.0, when the Set day and night is turned OFF and missed dose or Correct high glucose alerts are enabled, the associated alerts will not be triggered during the nighttime. This could result in missed rapid-acting insulin doses without the user s knowledge, and may lead to delayed therapy and an increased risk of hyperglycemia. Action: On 6/16/2026 In-App Push Notifications were sent to customers entitled, Important Field Safety Corrective Action required on your MiniMed Go ap...
Daily briefings, device safety watches, trial roundups, and research notes — each linked back to original sources.
A daily Type1Cure briefing built from current official and public source pulls, with each item labeled by source, evidence class, and family relevance.
A focused safety brief from the current FDA device recall lane, prioritizing CGM, pump, insulin-delivery, glucose-monitoring, and related diabetes-device records.
A plain-English watchlist of current recruiting Type 1 diabetes studies surfaced from ClinicalTrials.gov, with consent-first guardrails for families.
A daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
Greater Northwest Chapter
Several investigational treatments are now recruiting participants in the Pacific Northwest. Here's what you need to know about getting involved in clinical research.
Medpharm Global
Stem cell therapies and immune engineering are showing real promise in early trials, with some patients reaching insulin independence. But significant hurdles remain before these approaches become widely available.
American Diabetes Association
New research demonstrates that islet autoantibody screening can identify people in the early stages of Type 1 diabetes before symptoms appear. This advance could open doors to earlier intervention strategies.
T1D Treatments: Breakthroughs for Families
Vertex's investigational stem cell therapy zimislecel (VX-880) has shown early promise in clinical trials, but it remains years away from potential FDA approval. Here's where the research stands and what families should know.
New Shorts daily on YouTube and TikTok
What Antibody Screening Tells Us About Type 1 Diabetes Risk in Children
What Antibody Screening Tells Us About Type 1 Diabetes Risk in Children
A New App Aims to Make Type 1 Diabetes Management Less Overwhelming
A New App Aims to Make Type 1 Diabetes Management Less Overwhelming
New Pancreas Biomarkers Detected Early in Type 1 Diabetes Development
Pancreatic enzymes shift months before Type 1 appears.
What Happens After a Low: A New Drink Shows Promise for Faster Recovery
What Happens After a Low: A New Drink Shows Promise for Faster Recovery
New Genetic Links Between Type 1 Diabetes, Insulin Secretion, and Insulin Resistance
New Genetic Links Between Type 1 Diabetes, Insulin Secretion, and Insulin Resistance
New Study Reveals Sex and Weight Differences in Type 1 Diabetes Control in Young People
New Study Reveals Sex and Weight Differences in Type 1 Diabetes Control in Young People
Could Better Blood Sugar Control Help With Diabetic Nerve Pain? A New Study Is Testing It
Could Better Blood Sugar Control Help With Diabetic Nerve Pain? A New Study Is Testing It
Beyond Blood Tests: How Scientists Are Using Multiple Layers of Data to Better Predict Type 1 Diabetes Risk
Beyond Blood Tests: How Scientists Are Using Multiple Layers of Data to Better Predict Type 1 Diabetes Risk
Updated daily from ClinicalTrials.gov
Showing 6 of 8 programs tracked
Track all 8 programs →Chapter 5 — Age 17
“Closing in on seventeen, here's the short version of everything the younger me needed to hear.”
Closing in on seventeen, here's the short version of everything the younger me needed to hear.
Brooke's chapters are personal lived experience shared to make people feel less alone. They are not medical advice and do not describe a treatment plan. Talk to your own care team about your numbers, devices, and decisions.
If FDA, MedWatch, or a manufacturer issues a relevant CGM, pump, app, insulin, or glucagon alert, it should bypass the normal feed and hit the family alert lane first.
Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. ( Tandem ) has identified that certain Tandem Mobi insulin pumps may generate false-positive occlusion alarms when no actual insulin flow obstruction is present. Investigation determined that increased friction within the drive module can reduce available motor power and, under certain conditions, cause motor speed to fall below the occlusion detecti... Action: On 9/23/2026, "URGENT MEDICAL DEVICE CORRECTION" recall and correction notices were emailed to customers who were asked to do th...
Open alertMedtronic MiniMed, Inc.
A software defect in which existing users who had previously configured and enabled the long-acting dose reminder feature in version 1.2.0 or earlier experienced failure of the long-acting dose reminder after updating their app to version 1.2.1. The long-acting dose reminder is an optional feature that, when enabled, triggers a notification at the scheduled time to remind user... Action: On 09/14/2026, customers were contacted via SMS, emailed or via an "URGENT MEDICAL DEVICE CORRECTION" Letter informing them that...
Open alertA Randomized
RECRUITING, PHASE1, PHASE2. Interventions: Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab. Locations: Los Angeles, California, United States | San Francisco, California, United States | New Haven, Connecticut, United States. This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons a...
Open alertSAFety and
RECRUITING, PHASE2. Interventions: High Dose SAB-142, Low Dose SAB-142, Placebo. Locations: San Francisco, California, United States | San Jose, California, United States | Aurora, Colorado, United States. This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
Open alert